NCT02066636已完成3 期
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen
Bristol-Myers Squibb118 个研究点 分布在 2 个国家目标入组 1,428 人开始时间: 2014年4月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,428
- 试验地点
- 118
- 主要终点
- The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5)
研究概览
简要总结
The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Target Population
- •Subjects with histologically-or cytologically-documented NSCLC [squamous (SQ) or nonsquamous (NSQ)] who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for locally advanced disease)
- •Subjects must have experienced disease progression or recurrence during or after at least one systemic therapy for advanced or metastatic disease
- •Each subsequent line of therapy must be preceded by disease progression. A switch of an agent within a regimen in order to manage toxicity does not define the start of a new line of therapy
- •Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate regimen of therapy
- •Subjects who received platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, and developed recurrent (local or metastatic) disease within 6 months of completing therapy are eligible
- •Subjects with recurrent disease >6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy given for locally advanced disease, who also subsequently progressed during or after a platinum doublet-based regimen given to treat the recurrence are eligible
- •Subjects with non-squamous histology must be tested for Epithelial Growth Factor Receptor (EGFR) mutations (including, but not limited to, deletions in exon 19 and exon 21 [L858R] substitution) and Anaplastic Lymphoma Kinase (ALK) rearrangement if tests have not been previously performed. Subjects with progressive disease during or after EGFR or ALK tyrosine kinase inhibitor (TKI) regimens are eligible. Subjects are eligible if genetic test results are indeterminate or if no tumor tissue is available or accessible for testing as long as they have received one prior systemic therapy
- •Experimental therapies when given as separate regimen are considered as separate line of therapy
- •Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment performed within 28 days of first dose of study drug) or clinically apparent disease that the investigator can follow for response per RECIST 1.1
- •Eastern Cooperative Oncology Arm (ECOG) performance status (PS)
- •PS 0 to 1
排除标准
- •Target Disease Exceptions
- •Subjects with active central nervous system (CNS) metastases are excluded
- •Subjects with carcinomatous meningitis
- •Medical History and Concurrent Diseases
- •Subjects with a history of interstitial lung disease
- •Subjects with active, known or suspected autoimmune disease
- •Subject whom participated in either arm of the following clinical trials CA209-017, CA209-057, CA209-026, and CA184-104 or received prior treatment with anti-programmed death 1 (PD-1) or anti-programmed death-ligand 1 (PDL1) experimental agents
- •Prohibited Treatments and/or Restricted Therapies
- •Ongoing or planned administration of anti-cancer therapies other than those specified in this study
- •Use of corticosteroids or other immunosuppressive medications
研究组 & 干预措施
Cohort A: Nivolumab
Experimental
Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
干预措施: Nivolumab (Drug)
Cohort B: Nivolumab
Experimental
Nivolumab 3 mg/kg solution intravenous infusion over 30 minutes every two weeks until 1 year (52 weeks).
Discontinue treatment and at progression, retreatment allowed
干预措施: Nivolumab (Drug)
结局指标
主要结局
The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5)
时间窗: From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months)
A treatment related adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered an investigational (medicinal) product and that has a causal relationship with this treatment. The select AEs categories are those that are expected to be most commonly used to describe pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, and endocrinopathies and hypersensitivity/infusion reactions. AEs are graded according to NCI CTCAE (Version 4.0) guidelines where Grade 3= Severe, Grade 4 = Life-threatening, Grade 5 = Death.
次要结局
- Median Time to Onset of Select Adverse Events (Grade 3-5)(From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months))
- The Total Duration of All Immune Modulating Medications for Any Grade Select Adverse Events(From first dose first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months))
- Median Time to Resolution of Select Adverse Events (Grade 3-5)(From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months))
- The Number of Participants Who Received Immune Modulating Medication (or Hormonal Replacement Therapy) for Any Grade Select Adverse Events(From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months))
- The Number of Participants Who Received ≥ 40 mg Prednisone Equivalents for Any Grade Select Adverse Events(From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months))
- The Number of Participants With High Grade (Grade 3-4 and Grade 5) Select Adverse Events(From first dose and 100 days after last dose (last dose up to randomization for cohort B) (up to approximately 88 months))
研究者
研究点 (118)
Loading locations...
相似试验
已完成
2 期
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic RegimenMetastatic Renal Cell CarcinomaNCT03013335UNICANCER730
已完成
4 期
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaRenal Cell CarcinomaNCT02596035Bristol-Myers Squibb197
终止
1 期
Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung CancerSmall-cell Lung CancerSmall Cell Lung CarcinomaNCT04173325Augusta University10
已完成
3 期
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerVarious Advanced CancerNCT02632409Bristol-Myers Squibb709
已完成
1 期
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsSolid TumorsNCT02593786Bristol-Myers Squibb58